M-Life
Bringing Science to Life

Novel Molecule Development for the Treatment of Leukemia and Other Cancers

High Specificity, Three Mechanism, Low Toxicity, Chimeric & Single Mechanism Tubulin Molecules

M-Life
Bringing Science to Life

Leukemia and Brain cancer are the two most prevalent forms of cancer in children+

The two most fatal forms in all age groups are AML and GBM

+American Cancer Society 2021

M-Life
Bringing Science to Life

Current pediatric treatments are limited by drug toxicity

Many adult therapeutic regimens are not translatable to pediatric standards of care


M-Life
Bringing Science to Life
M-Life™ Chief Discovery Officer
A New Approach:
Targeting cancer
but not normal cells
Peter Crooks, PhD, D.Sci, FRSC, FRPharmS
World renown cancer researcher and drug developer

M-Life

Bringing Science to Life

What Makes Us Different

Traditional Medicinal Chemistry

Directed AI



Big Data Fusion



M-Life
Bringing Science to Life

Results to Date

Tubulin Inhibitors

- 8 high value assets identified via M-Life™ platforms and entire portfolio licensed (550)
- Synthesized and invitro tested by the National Cancer Institute NCI60 Panel
- Low toxicity and high efficacy profiles
- IP covered by 5 issued patents and licensed to M-Life™

MTA Chimeras (tubulin, glutathione & NFkB)

- 10 M-Life™ platform designed chimera molecules
- Lower toxicity than synthesized tubulin molecules with much higher efficacy
- Pediatric and adult therapeutic use profiles indicating use across most cancer types

M-Life
Bringing Science to Life

Platform Strengths

The ability to:

- Select ‘High Value Molecules’ from a sea of possibilities
- Identify the features responsible for toxicity & efficacy
- Design optimal molecules…VERY, VERY, VERY FAST & INEXPENSIVELY
- Identify new modes of action



M-Life
Bringing Science to Life

Strategy

Leverage Out Strengths: (1) Identify Low Tox, High Value Assets (2) Design Novel Molecules

<6-9 mos.	18-24 mos.	<12 mos.
Focus on Pediatric AML & GBM	FDA Fast Track Process	Exit via Sell-Off
Development • Chimera and Tubulin Added IP • Chimera Small Scale Synthesis • Chimera NCI60 Testing • Tubulin In vivo Mouse Testing	**Development** • API Scale-up via TCG • GLP Tox via CRO • IND • Possible Phase I	**Development** • Expand Use to other cancers • Select Next Programs
CDN Financing • CDN Approx. $500k • Ops Only Exp. • No Salary or Wages • Converts at Series A	**Series A Financing** • $10M+ Equity • Institutional • CDN Conversion	**Sale of Cancer Molecules** • > 100M up front • > 500M back end • Company Profits Re-Invested in New Programs

M-Life
Bringing Science to Life

Opportunity

Objective: Drive Favorable Series A Deal Terms

Convertible Debt Financing

- $10K Minimum
- 3 to 5X Multiplier
- Maximum Offering $500K
- 4 year Automatic Term Conversion



Use of Proceeds

- 3-5 Chimera Synthesis
- Chimera Molecule NCI 60 Testing
- 8 Licensed Tubulin Molecule *in vivo* Testing
- Chimera molecule IP
- NO SALARIES OR WAGES
- NO OFFICE/BACK-OFFICE SPACE
- NO COMMISSIONS OR BONUSES

M-Life
Bringing Science to Life

For more information:

Ted Moskal
President, CEO & Founder
Moskal Lifesciences, LLC
tmoskal@m-lifesciences.com
870.680.2141